HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - A proof of concept

Journal of Ovarian Research

Volumn 7, Issue 1, 2014, Pages

  Haas, Jigal ^a,b   Kedem, Alon ^a,b   Machtinger, Ronit ^a,b   Dar, Shir ^a,b   Hourvitz, Ariel ^a,b   Yerushalmi, Gil ^a,b   Orvieto, Raoul ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

GnRH agonist trigger; hCG rescue; Ovarian hyperstimulation syndrome; Ovarian stimulation; Prevention

Indexed keywords

CHORIONIC GONADOTROPIN; GONADORELIN AGONIST; PROGESTERONE; BIOLOGICAL MARKER; ESTRADIOL; ESTRADIOL VALERATE; FERTILITY PROMOTING AGENT; GONADORELIN; HORMONE ANTAGONIST; TRIPTORELIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FERTILIZATION IN VITRO; HUMAN; HUMAN CELL; LUTEAL PHASE; OOCYTE MATURATION; OVARY FOLLICLE CELL; OVARY HYPERSTIMULATION; PREGNANCY RATE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RISK; ADVERSE EFFECTS; AGONISTS; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; EMBRYO TRANSFER; METABOLISM; OOCYTE RETRIEVAL; OVARIAN HYPERSTIMULATION SYNDROME; OVARY FOLLICLE; OVULATION INDUCTION; PREGNANCY; PROCEDURES; TIME; TREATMENT OUTCOME;

ADULT; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EMBRYO TRANSFER; ESTRADIOL; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; LUTEAL PHASE; OOCYTE RETRIEVAL; OVARIAN FOLLICLE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; PROGESTERONE; TIME FACTORS; TREATMENT OUTCOME; TRIPTORELIN PAMOATE;

EID: 84898420980     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-7-35     Document Type: Article

References (18)

1. Ovarian hyperstimulation syndrome: a new insight into an old enigma. Orvieto R, Ben-Rafael Z, J Soc Gynecol Invest 1998 5 110 113 10.1016/S1071-5576(97)00113-5 (Pubitemid 28248534)
2. Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. Orvieto R, Ben-Rafael Z, Hum Reprod 1998 13 3306 3309 10.1093/humrep/13.12.3306 9886504 (Pubitemid 29002612)
3. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Kol S, Fertil Steril 2004 81 1 5 (Pubitemid 38058315)
4. Can we eliminate severe ovarian hyperstimulation syndrome? Orvieto R, Hum Reprod 2005 20 320 322 15567876 (Pubitemid 40277597)
5. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM, Hum Reprod Update 2006 12 159 168 16254001 (Pubitemid 43239269)
6. Substituting HCG with GnRH agonist to trigger final follicular maturation-a retrospective comparison of three different ovarian stimulation protocols. Orvieto R, Rabinson J, Meltzer S, Zohav E, Anteby E, Homburg R, Reprod Biomed Online 2006 13 198 201 10.1016/S1472-6483(10)60615-3 16895632 (Pubitemid 44207766)
7. GnRH agonist triggering: recent developments. Kol S, Humaidan P, Reprod Biomed Online 2013 26 226 230 10.1016/j.rbmo.2012.11.002 23337420
8. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin- releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Humaidan P, Bredkjaer HE, Westergaard LG, Andersen CY, Fertil Steril 2010 93 847 854 10.1016/j.fertnstert.2008.12.042 19200959
9. The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, Fatemi HM, Reprod Biomed Online 2012 24 134 141 10.1016/j.rbmo.2011.11.001 22197130
10. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH, Hum Reprod 2013 28 2522 2528 10.1093/humrep/det124 23633553
11. Ovarian hyperstimulation syndrome. The Practice Committee of the American Society for Reproductive Medicine (ASRM), Fertil Steril 2008 90 188 S193 19007627
12. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomised controlled study. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C, Fertil Steril 2008 89 84 91 10.1016/j.fertnstert.2007.02.002 17462639
13. Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma. Orvieto R, J Ovarian Res 2013 6 77 10.1186/1757-2215-6-77 24191960
14. Recovery of corpus luteum function after prolonged deprivation from gonadotrophin stimulation. Weissman A, Loumaye E, Shoham Z, Hum Reprod 1996 11 943 949 10.1093/oxfordjournals.humrep.a019329 8671368 (Pubitemid 26177259)
15. The corpus luteum of the primate menstrual cycle is capable of recovering from a transient withdrawal of pituitary gonadotropin support. Hutchison JS, Zeleznik AJ, Endocrinology 1985 117 1043 1049 10.1210/endo-117-3-1043 3893990 (Pubitemid 15020029)
16. The value of a single serum progesterone measurement in the midluteal phase as a criterion of a potentially fertile cycle ("ovulation") derived form treated and untreated conception cycles. Hull MG, Savage PE, Bromham DR, Ismail AA, Morris AF, Fertil Steril 1982 37 355 360 7060786 (Pubitemid 12183690)
17. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, Papanikolaou EG, Humaidan P, Fertil Steril 2013 100 742 747 10.1016/j.fertnstert.2013.05.028 23806846
18. Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help? Orvieto R, Reprod Biomed Online 2012 24 680 681 10.1016/j.rbmo.2012.03.005 22503268